SGTX. Market cap of 57 million From over $1 Billion dollars ..... https://www.stockwatch.com/Quote/Detail.aspx?U:SGTX
I believe Viacycte is also going no where . Their progenitor cells take at least 6 months before they differentiate into B cells and not all of their progenitor cells will mature enough to produce insulin. The immunosuppresion angle is key . Viacycte ha s joined up with Crispr but this gene editing is years away . The fact they are doing it in Canada speaks volumes.
Conformal coating is key, Sva has several preclinical studies in mice and primates . Conformal coating has been proven and adjusted to enhance efficacy.
The last leg of the stool is supply of stem cells. I believe Echelon analyst report alluded to the fact that a deal involving a pharma with proven stem cells is potentially coming .
Once management has all 3 legs of the stools in a clinical trial, only then will we serious upside in market cap.
Thyroid proof of concept and /or Hemophilia A in a limited trial in patients would add extreme value to market cap ... a few dollars possibly .
As time goes on, I believe Semma/Vertex is the real competiition for now, but to maintain market cap we have to move on clinical trials . I still think we are years away from a buyout but I don't see a medical device distribution company rushing in to sign a deal because the company is no where close for having a viable device approved and ready for the market.
Elgin